vs
海斯特耶鲁（HY）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
海斯特耶鲁的季度营收约是Royalty Pharma plc的1.5倍（$923.2M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs -5.7%，领先40.1%），Royalty Pharma plc同比增速更快（4.8% vs -13.5%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -6.5%）
海斯特-耶鲁物料搬运公司通过其全资运营子公司海斯特-耶鲁集团，主要以海斯特与耶鲁品牌在全球范围设计研发、生产销售全系列叉车，并提供售后配件与相关服务。该公司2002年起就在NACCO工业集团内独立运营，最终于2012年从NACCO分拆独立。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
HY vs RPRX — 直观对比
营收规模更大
HY
是对方的1.5倍
$622.0M
营收增速更快
RPRX
高出18.3%
-13.5%
净利率更高
RPRX
高出40.1%
-5.7%
两年增速更快
RPRX
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $923.2M | $622.0M |
| 净利润 | $-52.5M | $214.2M |
| 毛利率 | 14.2% | — |
| 营业利润率 | -4.0% | 62.4% |
| 净利率 | -5.7% | 34.4% |
| 营收同比 | -13.5% | 4.8% |
| 净利润同比 | -609.7% | 2.9% |
| 每股收益（稀释后） | $-2.97 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HYRPRX
| Q4 25 | $923.2M | $622.0M | ||
| Q3 25 | $979.1M | $609.3M | ||
| Q2 25 | $956.6M | $578.7M | ||
| Q1 25 | $910.4M | $568.2M | ||
| Q4 24 | $1.1B | $593.6M | ||
| Q3 24 | $1.0B | $564.7M | ||
| Q2 24 | $1.2B | $537.3M | ||
| Q1 24 | $1.1B | $568.0M |
净利润HYRPRX
| Q4 25 | $-52.5M | $214.2M | ||
| Q3 25 | $-2.3M | $288.2M | ||
| Q2 25 | $-13.9M | $30.2M | ||
| Q1 25 | $8.6M | $238.3M | ||
| Q4 24 | $10.3M | $208.2M | ||
| Q3 24 | $17.2M | $544.0M | ||
| Q2 24 | $63.3M | $102.0M | ||
| Q1 24 | $51.5M | $4.8M |
毛利率HYRPRX
| Q4 25 | 14.2% | — | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 17.6% | — | ||
| Q1 25 | 19.5% | — | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 19.0% | — | ||
| Q2 24 | 22.2% | — | ||
| Q1 24 | 22.3% | — |
营业利润率HYRPRX
| Q4 25 | -4.0% | 62.4% | ||
| Q3 25 | 0.2% | 70.1% | ||
| Q2 25 | -0.9% | 36.3% | ||
| Q1 25 | 2.3% | 94.0% | ||
| Q4 24 | 3.0% | 60.9% | ||
| Q3 24 | 3.3% | — | ||
| Q2 24 | 8.2% | 50.2% | ||
| Q1 24 | 7.9% | -13.0% |
净利率HYRPRX
| Q4 25 | -5.7% | 34.4% | ||
| Q3 25 | -0.2% | 47.3% | ||
| Q2 25 | -1.5% | 5.2% | ||
| Q1 25 | 0.9% | 41.9% | ||
| Q4 24 | 1.0% | 35.1% | ||
| Q3 24 | 1.7% | 96.3% | ||
| Q2 24 | 5.4% | 19.0% | ||
| Q1 24 | 4.9% | 0.8% |
每股收益（稀释后）HYRPRX
| Q4 25 | $-2.97 | $0.49 | ||
| Q3 25 | $-0.13 | $0.67 | ||
| Q2 25 | $-0.79 | $0.07 | ||
| Q1 25 | $0.48 | $0.55 | ||
| Q4 24 | $0.57 | $0.46 | ||
| Q3 24 | $0.97 | $1.21 | ||
| Q2 24 | $3.58 | $0.23 | ||
| Q1 24 | $2.93 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | $251.9M | $9.0B |
| 股东权益账面价值 | $472.0M | $9.7B |
| 总资产 | $2.0B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.53× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资HYRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务HYRPRX
| Q4 25 | $251.9M | $9.0B | ||
| Q3 25 | $252.2M | $8.9B | ||
| Q2 25 | $245.2M | $8.0B | ||
| Q1 25 | $242.6M | $7.6B | ||
| Q4 24 | $241.9M | $7.6B | ||
| Q3 24 | $247.4M | $7.6B | ||
| Q2 24 | $248.5M | $7.6B | ||
| Q1 24 | $239.7M | $6.1B |
股东权益HYRPRX
| Q4 25 | $472.0M | $9.7B | ||
| Q3 25 | $536.0M | $9.6B | ||
| Q2 25 | $544.7M | $9.5B | ||
| Q1 25 | $510.0M | $9.8B | ||
| Q4 24 | $475.1M | $10.3B | ||
| Q3 24 | $529.9M | $10.3B | ||
| Q2 24 | $465.7M | $9.8B | ||
| Q1 24 | $412.1M | $9.9B |
总资产HYRPRX
| Q4 25 | $2.0B | $19.6B | ||
| Q3 25 | $2.1B | $19.3B | ||
| Q2 25 | $2.1B | $18.3B | ||
| Q1 25 | $2.1B | $17.6B | ||
| Q4 24 | $2.0B | $18.2B | ||
| Q3 24 | $2.2B | $18.0B | ||
| Q2 24 | $2.1B | $17.7B | ||
| Q1 24 | $2.1B | $16.1B |
负债/权益比HYRPRX
| Q4 25 | 0.53× | 0.92× | ||
| Q3 25 | 0.47× | 0.93× | ||
| Q2 25 | 0.45× | 0.84× | ||
| Q1 25 | 0.48× | 0.78× | ||
| Q4 24 | 0.51× | 0.74× | ||
| Q3 24 | 0.47× | 0.74× | ||
| Q2 24 | 0.53× | 0.78× | ||
| Q1 24 | 0.58× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $56.5M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $32.9M | — |
| 自由现金流率自由现金流/营收 | 3.6% | — |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $23.6M | — |
8季度趋势，按日历期对齐
经营现金流HYRPRX
| Q4 25 | $56.5M | $827.1M | ||
| Q3 25 | $37.1M | $702.6M | ||
| Q2 25 | $28.9M | $364.0M | ||
| Q1 25 | $-36.4M | $596.1M | ||
| Q4 24 | $80.7M | $742.5M | ||
| Q3 24 | $70.1M | $703.6M | ||
| Q2 24 | $-2.5M | $658.2M | ||
| Q1 24 | $22.4M | $664.6M |
自由现金流HYRPRX
| Q4 25 | $32.9M | — | ||
| Q3 25 | $22.6M | — | ||
| Q2 25 | $15.1M | — | ||
| Q1 25 | $-47.0M | — | ||
| Q4 24 | $62.8M | — | ||
| Q3 24 | $59.9M | — | ||
| Q2 24 | $-14.7M | — | ||
| Q1 24 | $14.9M | — |
自由现金流率HYRPRX
| Q4 25 | 3.6% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | -5.2% | — | ||
| Q4 24 | 5.9% | — | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | -1.3% | — | ||
| Q1 24 | 1.4% | — |
资本支出强度HYRPRX
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 0.7% | — |
现金转化率HYRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | -4.23× | 2.50× | ||
| Q4 24 | 7.83× | 3.57× | ||
| Q3 24 | 4.08× | 1.29× | ||
| Q2 24 | -0.04× | 6.45× | ||
| Q1 24 | 0.43× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HY
| Sales Channel Through Intermediary | $281.7M | 31% |
| Aftermarketsales | $179.1M | 19% |
| Sales Channel Directly To Consumer | $173.6M | 19% |
| EMEAHY | $153.3M | 17% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $89.0M | 10% |
| Otherrevenue | $42.4M | 5% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
